References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailGrip strength measurement: Towards a standardized approach in sarcopenia research and practice
Schaap, L. A.; Fox, B.; Henwood, T. et al

in European Geriatric Medicine (2016), 7(3), 247-255

Introduction: Grip strength is a well-accepted measure of muscle strength. A standardized protocol for the measurement of grip strength has been proposed in 2011 to enable consistent measurement of grip ... [more ▼]

Introduction: Grip strength is a well-accepted measure of muscle strength. A standardized protocol for the measurement of grip strength has been proposed in 2011 to enable consistent measurement of grip strength and comparisons between studies. It is unknown whether this protocol has been adopted in sarcopenia research and practice. The aim of the study was to provide insight into current measurement practice, including the use of cut-off values for low muscle strength. Methods: A systematic review of the literature was conducted, followed by a methodological quality assessment and extraction of relevant data. Inclusion criteria included a description of the grip strength protocol, EWGSOP standards were used to define sarcopenia, data was collected after 2010 and participants were 65 years and older. Results: Twenty-seven observational papers were included in the review. The methodological quality was acceptable/good. Overall, information about the protocol was limited with a large variability in measurement approach. Most non-Asian studies used cut-off values for low grip strength of 30 kg for men and 20 kg for women. Asian studies showed more variability in choice of cut-off values. Discussion: The proposed grip strength measurement protocol has been poorly adopted since its publication. Although there seems to be some agreement on cut-off values in non-Asian studies, proposed cut-off values need to be evaluated in specific diseases and settings and its predictive abilities regarding outcomes such as mobility limitations and falls needs to be determined. Asian research on cut-off values is still ongoing. © 2015 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved. [less ▲]

Detailed reference viewed: 19 (0 ULiège)
Full Text
Peer Reviewed
See detailA comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement
Blain, H.; Masud, T.; Dargent-Molina, P. et al

in Journal of Nutrition, Health & Aging (2016), 20(6), 647-652

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest ... [more ▼]

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest Group on Falls and Fracture Prevention of the European Union Geriatric Medicine Society (EUGMS), in collaboration with the International Association of Gerontology and Geriatrics for the European Region (IAGG-ER), the European Union of Medical Specialists (EUMS), the International Osteoporosis Foundation - European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people. © 2016, Serdi and Springer-Verlag France. [less ▲]

Detailed reference viewed: 26 (0 ULiège)
Full Text
Peer Reviewed
See detailDenosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
Miller, P. D.; Pannacciulli, N.; Brown, J. P. et al

in Journal of Clinical Endocrinology and Metabolism (2016), 101(8), 3163-3170

Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the effect of transitioning from oral ... [more ▼]

Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover. Design and Setting: This was an international, multicenter, randomized, double-blind trial. Participants:Atotal of 643 postmenopausalwomenwith osteoporosis previously treated with oral bisphosphonates participated in the study. Interventions: Subjects were randomized 1:1 to scdenosumab60mgevery 6 months plus iv placebo once or ZOL 5 mg iv once plus sc placebo every 6 months for 12 months. Main Outcome Measures: Changes in BMD and bone turnover markers were measured. Results: BMD change from baseline at month 12 was significantly greater with denosumab compared with ZOL at the lumbar spine (primary end point; 3.2% vs 1.1%; P < .0001), total hip (1.9% vs 0.6%; P < .0001), femoral neck (1.2% vs -0.1%; P < .0001), and one-third radius (0.6% vs 0.0%; P < .05). The median decrease from baseline was greater with denosumab than ZOL for serum C-telopeptide of type 1 collagen at all time points after day 10 and for serum procollagen type 1 N-terminal propeptide at month 1 and at all time points after month 3 (all P < .05). Median percentage changes from baseline in serum intact PTH were significantly greater at months 3 and 9 with denosumab compared with ZOL (all P < .05). Adverse events were similar between groups. Three events consistent with the definition of atypical femoral fracture were observed (two denosumab and one ZOL). Conclusions: In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greaterBMDincreases at all measured skeletal sites and greater inhibition of bone remodeling compared with ZOL. [less ▲]

Detailed reference viewed: 14 (0 ULiège)
Full Text
Peer Reviewed
See detailA comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
Blain, H.; Masud, T.; Dargent-Molina, P. et al

in European Geriatric Medicine (2016), 7(6), 519-525

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest ... [more ▼]

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) – European society for clinical and economic aspects of osteoporosis and osteoarthritis (ECCEO), outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people. © 2016 [less ▲]

Detailed reference viewed: 59 (0 ULiège)
Full Text
Peer Reviewed
See detailA randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate.
MILLER, P.D.; PANNACCIULLI, N.; BROWN, J.P. et al

in Arthritis and Rheumatology (2016), 67(S10), 1181-1182

Detailed reference viewed: 55 (2 ULiège)
Full Text
Peer Reviewed
See detailRelationship between frailty, physical performance and quality of life among nursing home residents: the SENIOR cohort
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Petermans, Jean ULiege et al

in Aging Clinical and Experimental Research (2016), 28(6), 1149-57

Background The aim of this study was to assess the relationship between frailty and a large number of indicators related to physical and muscular performance as well as quality of life. Methods This is an ... [more ▼]

Background The aim of this study was to assess the relationship between frailty and a large number of indicators related to physical and muscular performance as well as quality of life. Methods This is an analysis of data collected at baseline in the Sample of Elderly Nursing home Individuals: an Observational Research (SENIOR) cohort including nursing home residents. Subjects are volunteer, oriented and able to walk (walking assistance allowed) nursing home residents in Belgium. A large number of demographic and clinical characteristics, including physical and muscular performance, were collected from each patient. The prevalence of frailty in this population was assessed using Fried’s definition. Results In total, 662 subjects are included in this analysis. The mean age of the sample is 83.2 ± 8.99 years, and 484 (73.1 %) are women. In this population of nursing home residents, the prevalence of frailty is 25.1 %, pre-frailty, 59.8 % and robustness, 15.1 %. Compared to non-frail subjects, frail subjects have lower physical and muscular performances and a lower quality of life. Conclusion Frailty, according to Fried’s definition, seems to be associated with several clinical indicators suggesting a higher level of disability and an increased propensity to develop major clinical consequences. Follow-up data of the SENIOR cohort will be helpful in confirming these findings, establishing cause–effect relationships and identifying the most predictive components of physical frailty for adverse outcomes in nursing homes. [less ▲]

Detailed reference viewed: 53 (16 ULiège)
Full Text
Peer Reviewed
See detailSarcopenia as a public health problem
Bruyère, Olivier ULiege; Beaudart, Charlotte ULiege; Locquet, Médéa ULiege et al

in European Geriatric Medicine (2016), 7(3), 272-5

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an ... [more ▼]

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an effective treatment. In this paper, we review the main current literature on sarcopenia in order to assess whether this geriatric syndrome could be considered as a major public health problem. Our review highlights that based on its prevalence, its clinical consequences, the limitations of the current available treatments as well as on the fact that many frail patients are affected by this geriatric syndrome, sarcopenia should be considered as a health priority by all interested parties in order to reduce its burden. [less ▲]

Detailed reference viewed: 56 (15 ULiège)
Full Text
See detailOstéoporose et sarcopénie: un même combat ?
Locquet, Médéa ULiege; Bruyère, Olivier ULiege; Beaudart, Charlotte ULiege et al

in Ortho-Rhumato (2016), 14(4), 34-36

L’ostéoporose et la sarcopénie exposent les individus âgés à un risque accru de chutes et de fractures, mais aussi à une altération de leur qualité de vie, à divers handicaps et à une augmentation de la ... [more ▼]

L’ostéoporose et la sarcopénie exposent les individus âgés à un risque accru de chutes et de fractures, mais aussi à une altération de leur qualité de vie, à divers handicaps et à une augmentation de la morbidité et de la mortalité. Elles représentent toutes deux un problème de santé publique grandissant, impliquant également des coûts de santé importants. Certaines études récentes confirment l’existence d’une unité fonctionnelle «os-muscle», concernant notamment ses aspects biologiques, hormonaux, développementaux ou encore génétiques. Actuellement, quelques études scientifiques démontrent également l’existence de voies communes dans la pathogenèse de la perte de masse musculaire et de masse osseuse. Certains auteurs suggèrent que les dysfonctionnements de cette unité fonctionnelle «os-muscle» pourraient éventuellement conduire à une pathologie spécifique, affectant les deux structures et pour lequel le terme «ostéosarcopénie» a été proposé. Cependant, jusqu’à présent, l’étroite relation entre muscles et os reste très peu explorée par les études cliniques en ce qui concerne ses aspects pathologiques et, plus particulièrement, le lien existant entre sarcopénie et ostéoporose, ses déterminants et ses conséquences. Ce manque de connaissances implique donc des retentissements considérables pour les politiques de santé publique, principalement concernant les stratégies préventives et thérapeutiques susceptibles d’être proposées aux personnes âgées. [less ▲]

Detailed reference viewed: 67 (8 ULiège)
Full Text
Peer Reviewed
See detailUnmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
Ferrari, S.; Reginster, Jean-Yves ULiege; Brandi, M.L. et al

in Archives of Osteoporosis (2016), 11

Summary: This review provides a critical analysis of currently available approaches to increase bone mass, structure and strength through drug therapy and of possible direct intraosseous interventions for ... [more ▼]

Summary: This review provides a critical analysis of currently available approaches to increase bone mass, structure and strength through drug therapy and of possible direct intraosseous interventions for the management of patients at imminent risk of hip fracture. Purpose : Osteoporotic hip fractures represent a particularly high burden in morbidity-, mortality- and health care-related costs. There are challenges and unmet needs in the early prevention of hip fractures, opening the perspective of new developments for the management of osteoporotic patients at imminent and/or at very high risk of hip fracture. Amongst them, preventive surgical intervention needs to be considered. Methods: A European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)/International Osteoporosis Foundation (IOF) working group reviewed the presently available intervention modalities including preventive surgical options for hip fragility. This paper represents a summary of the discussions. Results: Prevention of hip fracture is currently based on regular physical activity; prevention of falls; correction of nutritional deficiencies, including vitamin D repletion; and pharmacological intervention. However, efficacy of these various measures to reduce hip fractures is at most 50% and may need months or years before becoming effective. To face the challenges of early prevention of hip fractures for osteoporotic patients at imminent and/or at very high risk of hip fracture, preventive surgical intervention needs further investigation. Conclusion: Preventive surgical intervention needs to be appraised for osteoporotic patients at imminent and/or at very high risk of hip fracture. [less ▲]

Detailed reference viewed: 16 (0 ULiège)
Full Text
Peer Reviewed
See detailA comprehensive fracture prevention strategy in older adults : the European Union Geriatric Medicine Society (EUGMS) statement.
Blain, H.; Masud, T.; Dargent-Molina, P. et al

in Aging Clinical and Experimental Research (2016), 28

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest ... [more ▼]

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest Group on Falls and Fracture Prevention of the European Union Geriatric Medicine Society, in collaboration with the International Association of Gerontology and Geriatrics for the European Region, the European Union of Medical Specialists, and the International Osteoporosis Foundation–European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people. [less ▲]

Detailed reference viewed: 17 (0 ULiège)
Full Text
Peer Reviewed
See detailIncidence of bone fractures after critical illness
ROUSSEAU, Anne-Françoise ULiege; Michel, Laure ULiege; Bawin, Maxime ULiege et al

in Intensive Care Medicine Experimental (2016), 4(Suppl 1), 1131

Detailed reference viewed: 23 (8 ULiège)
Full Text
Peer Reviewed
See detailPotential cost-effectiveness for using patient decision aids to guide osteoporosis treatment
Penton, H; Hiligsmann, M.; Harrison, M. et al

in Osteoporosis International (2016), 27

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence ... [more ▼]

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence, and only marginally increased time physicians needed with their patients, then the decision-aid would be cost-effective. Introduction Oral bisphosphonates have been shown to reduce the risk of osteoporotic fracture. Adherence is crucial but suboptimal. A recent study suggests that a patient decision aid, which facilitates shared decision-making, could be effective in increasing adherence to bisphosphonates. But decision aids come at a cost in terms of additional time spent with physicians. This study considers the emerging evidence on the role of patient decision aids in improving adherence to bisphosphonates and their potential costs to inform future decision-making and research priorities. [less ▲]

Detailed reference viewed: 19 (0 ULiège)
Full Text
Peer Reviewed
See detailA Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.
Detilleux, Johann ULiege; REGINSTER, Jean-Yves ULiege; Chines, A. et al

in Statistical Methods in Medical Research (2016), 25(1), 400-412

Background/Aims Bone mass density values have been related with risk of vertebral fractures in post-menopausal women. However, bone mass density is not perfectly accurate in predicting risk of fracture ... [more ▼]

Background/Aims Bone mass density values have been related with risk of vertebral fractures in post-menopausal women. However, bone mass density is not perfectly accurate in predicting risk of fracture, which decreases its usefulness as a surrogate in clinical trials. We propose a modeling framework with three interconnected parts to improve the evaluation of bone mass density accuracy in forecasting fractures after treatment. Methods The modeling framework includes: (1) a piecewise regression to describe non-linear temporal BMD changes more accurately than crude percent changes, (2) a structural equation model to analyze interdependencies among vertebral fractures and their potential risk factors in preference to regression techniques that consider only directional associations, and (3) a counterfactual causal interpretation of the direct and indirect relationships between treatment and occurrence of vertebral fractures. We apply the methods to BMD repeated measurements from a study of the effect of bazedoxifene acetate on incident vertebral fractures in three different geographical regions. Results We made four observations: (1) bone mass density changes varied largely across participants, (2) baseline age and body mass index influenced baseline bone mass density that, in turn, had an effect on prevalent fractures, (3) direct and/or indirect effects of bazedoxifene acetate on incident fractures were different across regions, and (4) estimates of indirect effects were sensible to the presence of post-treatment unmeasured confounders. In one region, around 40% of the bazedoxifene acetate effect on the occurrence of fracture is explained by its effect on bone mass density. Under the counterfactual approach, these 40% represent the average difference in the occurrence of fracture observed for untreated individuals when their bone mass density values are set at the value under bazedoxifene acetate versus under placebo. Conclusions Computational methods are available to evaluate and interpret the surrogacytic capability of a biomarker of a primary outcome. © SAGE Publications 2012. [less ▲]

Detailed reference viewed: 61 (20 ULiège)
Full Text
Peer Reviewed
See detailHigh Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study
Edwards, M.H.; Parsons, C.; Bruyère, Olivier ULiege et al

in Journal of Rheumatology (2016), 43(3), 657-65

Objective. Determinants of radiographic progression in osteoarthritis (OA) are poorly understood. We investigated which features on baseline magnetic resonance imaging (MRI) acted as predictors of change ... [more ▼]

Objective. Determinants of radiographic progression in osteoarthritis (OA) are poorly understood. We investigated which features on baseline magnetic resonance imaging (MRI) acted as predictors of change in joint space width (JSW). Methods. A total of 559 men and women over the age of 50 years with clinical knee OA [Kellgren-Lawrence (KL) grade 2-3] were recruited to the placebo arm of the SEKOIA study (98 centers; 18 countries). Minimal tibiofemoral joint space and KL grade on plain radiograph of the knee were assessed at baseline and at yearly followup up to 3 years. In a subset, serial knee MRI examinations were performed. Individuals with a bone marrow lesion (BML) ≥ grade 2 at the tibiofemoral joint at baseline were classified as BML-positive. Relationships between change in JSW and risk factors were assessed using linear regression. Results. The mean age of study participants was 62.8 (SD 7.5) years and 73% were female; 38.6% had BML. Mean baseline JSW was 3.65 mm. This reduced by 0.18 (0.30) mm/year in men and 0.13 (0.23) mm/year in women. Those with BML had a significantly higher rate of annualized change in JSW; this relationship remained robust after adjustment for age, sex, and baseline KL grade [β = –0.10 (95% CI –0.18, –0.02) mm/yr]. Age, sex, baseline KL grade, and other MRI findings did not influence the rate of change in JSW. Conclusion. The rate of change in JSW was similar in men and women. BML on knee MRI predicted the rate of radiographic change in JSW. This relationship was independent of age, sex, and baseline KL grade. (First Release January 15 2016; J Rheumatol 2016;43:657–65; doi:10.3899/jrheum.150053) [less ▲]

Detailed reference viewed: 27 (2 ULiège)
Full Text
Peer Reviewed
See detailClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
SMOLEN, J.S.; COLLAUD BASSET, S.; BOERS, M. et al

in Annals of Rheumatic Diseases (2016), 75

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial methodology to comment on the new draft ‘Guideline on clinical investigation of medicinal products for the treatment of RA’ released by the European Medicines Agency (EMA). Special emphasis was placed by the group on the development of new drugs for the treatment of early RA. In the absence of a clear definition of early RA, it was suggested that clinical investigations in this condition were conducted in disease-modifying antirheumatic drugs naïve patients with no more than 1 year disease duration. The expert group recommended using an appropriate improvement in disease activity (American College of Rheumatology (ACR) or Simplified/Clinical Disease Activity Index (SDAI/CDAI) response criteria) or low disease activity (by any score) as primary endpoints, with ACR/European League Against Rheumatism remission as a secondary endpoint. Finally, as compelling evidence showed that the Disease Acrivity Score using 28-joint counts (DAS28) might not provide a reliable definition of remission, or sometimes even low disease activity, the group suggested replacing DAS28 as a measurement instrument to evaluate disease activity in RA clinical trials. Proposed alternatives included SDAI, CDAI and Boolean criteria. [less ▲]

Detailed reference viewed: 33 (2 ULiège)
Full Text
Peer Reviewed
See detailRecommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Reginster, Jean-Yves ULiege; Cooper, Cyrus; Rizzoli, René et al

in Aging Clinical and Experimental Research (2016), 28(1), 47-58

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a ... [more ▼]

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. Methods: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. Results A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a pleais made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. Conclusions : The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk. [less ▲]

Detailed reference viewed: 35 (5 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study
Locquet, Médéa ULiege; Beaudart, Charlotte ULiege; Reginster, Jean-Yves ULiege et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 84

Detailed reference viewed: 15 (0 ULiège)
Full Text
Peer Reviewed
See detailBrain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations
CAVALIER, Etienne ULiege; Carlisi, A.S.; WATAR, Florence ULiege et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 116

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailPhysical and muscle performances among elderly nursing home residents. Results fo the senior cohort
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; CROISIER, Jean-Louis ULiege et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 69

Detailed reference viewed: 18 (1 ULiège)